Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C)
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company is presenting six posters at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14, 2023.
The posters, which include both clinical and preclinical data on the nonalcoholic steatohepatitis (NASH) program, ALG-055009, currently in Phase 2-enabling studies, as well as preclinical and clinical data from the chronic hepatitis B (CHB) portfolio, will be available on the Aligos website in the section following the conclusion of the conference.
Poster Details (all times are ET)
Title: Safety, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of ALG-055009, a thyroid hormone receptor beta agonist, in hyperlipidaemic subjects and relative bioavailability/food effect of a solid formulation in healthy volunteers
Poster Number: 2900-A
Abstract Number: 41459
Presenter: Stanley Wang, M.D., Ph.D.
Date and Time: Saturday, November 11, 1-2 pm
Title: Nonclinical efficacy, pharmacokinetic/pharmacodynamic (PK/PD), and toxicology profile of ALG-055009, a novel and potent thyroid hormone receptor β agonist, for the treatment of non-alcoholic steatohepatitis (NASH)
Poster Number: 2461-C
Abstract Number: 44177
Presenter: Dinah Misner, Ph.D.
Date and Time: Saturday, November 11, 1-2 pm
Title: Preclinical resistance profile and antiviral activity of the best-in-class CAM-E ALG-001075, the parent compound of ALG-000184
Poster Number: 1482-C
Abstract Number: 45229
Presenter: Andreas Jekle, Ph.D.
Date and Time: Friday, November 10, 1-2 pm
Title: Class A CAMs induce cell death through HBV core protein aggregation and potentially activate the innate immune response
Poster Number: 1462-C
Abstract Number: 44476
Presenter: Taverniti Valerio, Ph.D.
Date and Time: Friday, November 10, 1-2 pm
Title: Prolonged (>24 week) dosing with the oral CAM-E compound ALG-000184 results in multi-log reductions in hepatitis B surface antigen, HBV DNA, and HBV RNA levels in untreated E antigen positive subjects with chronic hepatitis B
Poster Number: 1483-C
Abstract Number: 41220
Presenter: Junqi Niu, M.D.
Date and Time: Friday, November 10, 12-1 pm
Title: Discovery of a liver targeted oral PD-L1 small molecule inhibitor for the treatment of chronic hepatitis B and liver cancer
Poster Number: 1466-C
Abstract Number: 44918
Presenter: Tongfei Wu, Ph.D.
Date and Time: Friday, November 10, 1-2 pm
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best in class therapeutics for nonalcoholic steatohepatitis (NASH) and viruses with high unmet medical need such as coronaviruses and chronic hepatitis B (CHB).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts and changes in the competitive landscape. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2023 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Media Contact
Veronica Eames
LifeSci Communications
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
